For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- Domestic Ethical Drug Market Estimated to Reach 9,617.7 Billion Yen in 2020: Fuji Keizai
November 22, 2013
- Takeda Deploys Cardiovascular, Diabetes Sales Reps for Comprehensive Detailing Activities for Lifestyle Diseases
November 22, 2013
- Mid-sized Foreign Drug Makers Eying Full-scale Entry into Japanese Market Encouraged by Favorable Changes in Market Environment; Marketing Systems May Be Key to Success
November 22, 2013
- Japan Diovan Sales Down 15.7% in July-September: IMS
November 22, 2013
- Japan Now Part of Global PIII Clinical Study for MLN9708: Takeda
November 21, 2013
- Novartis’ Compliance Advisory Board Holds 1st Meeting amid Diovan Fuss
November 21, 2013
- JT’s Anti-HIV Agent Elvitegravir Wins European Regulatory Approval
November 21, 2013
- Bristol-Myers Italy Head Piras Sworn in as Japan President
November 21, 2013
- Shionogi Licenses 2 Oxycodone Products with Abuse-Deterrent Measures from Mundipharma
November 21, 2013
- US Pfizer Plans Simultaneous, Global Filing of Five Biosimilars, Eyes Japan Biosimilar Market Entry
November 20, 2013
- Nichi-Iko to Collaborate with Hanoi Pharmaceutical of Vietnam
November 20, 2013
- Takeda, Eisai Earnings Show Signs of Bottoming Out, on Path to Recovery
November 18, 2013
- CMIC Chairman Sorry for Alleged Clinical Data Tampering; Probe Report Due out Late November
November 18, 2013
- PIII Study of Brexpiprazole Starts in US and Europe for Treatment of Agitation in AD: Otsuka Holdings
November 18, 2013
- Sales of Major Japanese Drug Makers Soar 8.1% on Weak Yen, Steady Japan Business
November 15, 2013
- Chugai Puts Off NHI Price Listing for Kadcyla, Agreement Not Reached
November 15, 2013
- Otsuka Holdings Notches Double-Digit Sales Growth in April-September, Weaker Yen Comes as Boon
November 14, 2013
- Chugai Obtains Exclusive Commercialization Rights for Anamorelin in Europe from Helsinn
November 14, 2013
- Kenko.com Sues Government to Affirm Right to Sell Prescription Drugs Online
November 14, 2013
- Generic Market Continues to Grow, Three Generic-Only Makers’ Sales Up 8.8%
November 13, 2013
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…